SOPHiA GENETICS Enters into Collaborate with AstraZeneca to Expand Global Access to Liquid Biopsy Testing

Overview

SOPHiA GENETICS has announced a major step forward in expanding its liquid biopsy test, MSK-ACCESS®, powered by SOPHiA DDM™. 

Liquid biopsy testing offers a less invasive alternative to traditional tissue biopsies, which are sometimes unsuitable due to low-quality samples or invasive procedures. It works by isolating cell-free DNA (cfDNA) from blood plasma, enabling the detection of circulating tumour DNA (ctDNA) through a simple blood test. This method is easier on patients and allows for quicker results, supporting faster clinical decision-making.

About MSK-ACCESS®

• MSK-ACCESS® powered with SOPHiA DDM™ was originally developed by Memorial Sloan Kettering Cancer Center (MSK), a leading cancer research institution. 
• This test is now decentralised, using the advanced analytical capabilities and cloud-based platform of SOPHiA DDM™. 
• Combining this technology with MSK’s expertise in cancer genomics provides a cutting-edge liquid biopsy solution.

This expansion follows a partnership agreement with AstraZeneca, with plans to roll out the test to 20 global locations over the next 12 months.

About the Collaboration

• The collaboration between SOPHiA GENETICS and AstraZeneca aims to make liquid biopsy tests more widely available and highlight their advantages over traditional tissue testing in certain cases. 
• A real-world evidence study will further examine the operational benefits, including faster results and high-quality data from a variety of lab settings.
• SOPHiA’s partnership with AstraZeneca could significantly boost access to liquid biopsy testing, particularly in underserved regions, potentially transforming cancer diagnostics, treatment, and monitoring globally.

Leading Healthcare Adopting the Test

• Since launching MSK-ACCESS® powered with SOPHiA DDM™ in April 2024, 14 leading healthcare institutions worldwide have adopted the test. 
• These include renowned cancer centres and labs in the US, Canada, Brazil, Germany, the UK, Norway, France, Nigeria, Taiwan, and India.

About AstraZeneca’s Involvement for Test Adoption

• AstraZeneca’s involvement is expected to further accelerate the adoption of this liquid biopsy test globally. 
• As more hospitals and labs adopt the technology, SOPHiA GENETICS and AstraZeneca, in collaboration with leading cancer institutes, will gather valuable real-world data that could significantly advance cancer research and treatment options.

AstraZeneca’s emphasised its commitment to bringing liquid biopsy expertise to labs around the world, ensuring better access to testing and data-driven treatment options for cancer patients globally.

About the Initiative

This initiative, first announced in October 2023, is a collaborative effort between SOPHiA GENETICS, AstraZeneca, and MSK, aimed at reducing health inequalities and pushing forward cancer research globally.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!